Idexx Laboratories Inc /DeIDXX

IDEXX Laboratories is not a tech platform, a blockchain water token, or a metaverse petri dish-it is a 35-year-old company that sells plastic trays, fluorescent powders, and $382 million of inventory to people who care whether their drinking water contains E. coli. The quarter ending 31 March 2026 shows revenue of $1.14 billion, net income of $278.4 million, and diluted EPS of $3.47, all filed in the company’s 10-Q. What’s harder to file is the realisation that, even after shrinking inventory by $2.2 million, the company still holds enough test kits to outfit a large operating program’s public health lab. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000114/000087471626000114.htm)

The business itself is as unsexy as a Bunsen burner: IDEXX sells water-microbiology systems and related consumables to labs, utilities, and governments. The portfolio includes the IDEXX Tecta system for automated microbiology, the UV Viewer PLUS for reading fluorescent plates, and a family of presence/absence and quantification kits (Legiolert, Colilert, Enterolert, Pseudalert) that have become institutional fixtures. The company also bundles proficiency testing and quality-control services, ensuring that labs stay accredited without having to invent their own QC programmes. (source: Official product/news rail, https://www.idexx.com/en/water/water-products-services/idexx-qc/)

On the numbers side, IDEXX is a cash machine: operating income of $362.6 million, cash and equivalents of $200.5 million, and net cash from operating activities of $266.2 million for the quarter. Capex was a modest $32 million, while R&D clocked in at $65.8 million-numbers that suggest a company still investing in its core franchises rather than chasing vapourware. Stockholders’ equity stands at $1.56 billion against $1.83 billion of liabilities, giving the balance sheet a sturdy, if not immaculate, look. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/874716/000087471626000114/000087471626000114.htm)

The company’s shareholder base often fixates on the frequent Forms 4 and 144 filed by executives, including CEO Jonathan Ayers, whose latest sale topped $4 million. The optics are awkward when the diluted weighted average share count sits at 80.2 million and EPS is a healthy $3.47-hardly a moment that screams “need liquidity.” The board’s disclosure cadence is technically compliant, yet it lands like a polite cough in a quiet room. (source: SEC EDGAR, URL: https://www.sec.gov/Archives/edgar/data/874716/000087471626000114/xslF345X06/wk-form4_1780434004.xml)

If the market wants a chart, TradingView shows IDEXX Laboratories Inc /DE (ticker: IDXX) bouncing between $400 and $450 on the Nasdaq, a range that tells you more about the liquidity of its shares than the efficacy of its water tests. The company is large enough, cash-generative enough, and boring enough that its share price moves are driven by flows and sentiment rather than corporate events. (source: TradingView chart route, https://www.tradingview.com/chart/)

What remains thin is any public disclosure on segment-level margins, customer concentration, or forward guidance beyond the headline numbers. The filings give us a company that prints cash but do not tell us which products are driving the growth or whether utilities are finally upgrading their fleets after years of procrastination. Until IDEXX releases a deeper segment breakout or an investor day with granular KPIs, the file keeps one eye on the lab bench and the other on the board’s filing calendar. (source: SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=874716)